October 1, 2012
Novartis Pharma said on September 28 that it received approval for its Seebri Inhalation Capsules 50 μg (glycopyrronium bromide), a treatment for chronic obstructive pulmonary diseases (COPD), on the same day. Upon its NHI listing, the drug will be copromoted...read more